Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.44 |
| ▸ | CFD | P00746 | 11/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | CMA1 | P23946 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627914 | 0.92 | METTL3 (0.46) | METTL3CFDNOTUMCMA1PPARG | |
| SCHEMBL3624158 | 0.90 | METTL3 (0.47) | METTL3CFDNOTUMCMA1PPARG | |
| SCHEMBL3627433 | 0.89 | METTL3 (0.40) | METTL3CFDNOTUMCMA1 | |
| SCHEMBL3628889 | 0.87 | METTL3 (0.39) | METTL3CFDNOTUMCMA1 | |
| SCHEMBL3624708 | 0.87 | METTL3 (0.44) | METTL3CFDNOTUMCMA1PPARG | |
| SCHEMBL3628451 | 0.87 | METTL3 (0.42) | METTL3CFDNOTUMCMA1P2RX7 | |
| SCHEMBL3620356 | 0.86 | METTL3 (0.40) | METTL3CFDNOTUMCMA1 | |
| SCHEMBL3615770 | 0.85 | METTL3 (0.38) | METTL3CFDNOTUMCMA1PPARG | |
| SCHEMBL3623481 | 0.85 | METTL3 (0.41) | METTL3CFDNOTUMCMA1P2RX7 | |
| SCHEMBL3624155 | 0.85 | METTL3 (0.42) | METTL3CFDNOTUMCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | claimed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | claimed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | METTL3 3971/4885CFD 4484/4885NOTUM 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.